P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 20.93 CNY -0.05% Market Closed
Market Cap: 15.3B CNY
Have any thoughts about
Pacific Shuanglin Bio pharmacy Co Ltd?
Write Note

Pacific Shuanglin Bio pharmacy Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pacific Shuanglin Bio pharmacy Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Additional Paid In Capital
ÂĄ4.8B
CAGR 3-Years
0%
CAGR 5-Years
110%
CAGR 10-Years
45%
Beigene Ltd
HKEX:6160
Additional Paid In Capital
ÂĄ81.4B
CAGR 3-Years
15%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Additional Paid In Capital
ÂĄ27.5B
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Additional Paid In Capital
ÂĄ3.3B
CAGR 3-Years
95%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Additional Paid In Capital
ÂĄ3.5B
CAGR 3-Years
-1%
CAGR 5-Years
90%
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
15.3B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
33.41 CNY
Undervaluation 37%
Intrinsic Value
Price
P

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
4.8B CNY

Based on the financial report for Sep 30, 2024, Pacific Shuanglin Bio pharmacy Co Ltd's Additional Paid In Capital amounts to 4.8B CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
45%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top